Breaking News Instant updates and real-time market news.

ROG

Rogers Corporation

$120.91

4.19 (3.59%)

, KRNT

Kornit Digital

$18.00

(0.00%)

07:14
07/10/18
07/10
07:14
07/10/18
07:14

CJS Securities to hold a conference

18th Annual "New Ideas" Summer Conference will be held in White Plains, NY on July 10.

ROG

Rogers Corporation

$120.91

4.19 (3.59%)

KRNT

Kornit Digital

$18.00

(0.00%)

GFF

Griffon

$18.15

-0.05 (-0.27%)

KBAL

Kimball International

$16.90

0.44 (2.67%)

TACO

Del Taco

$14.45

-0.19 (-1.30%)

  • 10

    Jul

  • 03

    Aug

ROG Rogers Corporation
$120.91

4.19 (3.59%)

12/19/17
NEED
12/19/17
NO CHANGE
Target $180
NEED
Buy
Rogers Corporation price target raised to $180 from $165 at Needham
Needham analyst Sean Hannan raised his price target on Rogers Corp to $180 after "positive" investor meetings with the company management. Hannan says the "niche-dominating" company continues to see "good growth" in specialized markets requiring its engineered materials. The analyst says he is especially enthusiastic about favorable trends in Advanced Mobility, Advanced Connectivity and Safety as they benefit from automotive technology improvements.
08/02/17
NEED
08/02/17
NO CHANGE
Target $135
NEED
Buy
Rogers Corporation price target raised to $135 from $115 at Needham
Needham analyst Sean Hannan raised his price target for Rogers Corporation to $135 from $115 after the company posted yet "another strong" quarterly result and guidance as the diversified model and market exposure is benefitting from cyclical and secular tailwinds that uniquely play into its strengths and emerging technology niche dominance. The analyst reiterates a Buy rating on the shares.
08/18/17
NEED
08/18/17
NO CHANGE
Target $135
NEED
Buy
Needham sees further upside in Rogers Corporation
Needham analyst Sean Hannan found Rogers Corporation's analyst positive and believes the company's 2020 earnings target of $7.90 looks conservative. The analyst sees further upside in the stock and keeps a Buy rating on Rogers with a $135 price target.
KRNT Kornit Digital
$18.00

(0.00%)

01/24/18
LSCM
01/24/18
NO CHANGE
Target $18
LSCM
Buy
StarTek price target raised to $18 after Amazon deal announcement at Lake Street
Lake Street analyst Mark Argento said the opportunity to sign a large, long-term agreement with Amazon (AMZN) is a "big win" for StarTek (SRT). He believes Amazon could contribute $100M in revenue and $10M-$12M in adjusted EBITDA for StarTek in 2019. Argento also noted that Amazon has executed deals like this in the past with other small public companies - such as Plug Power (PLUG), Air Transport Services (ATSG) and Kornit Digital (KRNT) - with favorable results to both fundamentals and equity values. He raised his price target on StarTek to $18 from $13 citing the value of the deal and keeps a Buy rating on the shares.
04/13/18
ADAM
04/13/18
NO CHANGE
Target $18
ADAM
Buy
Kornit Digital management meeting increases conviction, says Canaccord
Canaccord analyst Bobby Burleson met with the CEO of Kornit Digital and came away with increased conviction in his 2018 estimates. He also believes the current valuation is an attractive entry point for investors as he expects multiple expansion from recovering growth rates driven by the Avalanche HD sales/upgrade cycle. Burleson reiterated his Buy rating and $18 price target on Kornit Digital shares.
06/07/18
STFL
06/07/18
INITIATION
Target $21
STFL
Buy
Kornit Digital resumed with a Buy at Stifel
Stifel analyst Patrick Ho resumed coverage of Kornit Digital with a Buy rating and $21 price target, saying he believes 2018 will be a "rebound year" with momentum that will carry into strong growth for 2019 as well.
01/23/18
SBSH
01/23/18
UPGRADE
Target $19
SBSH
Buy
Kornit Digital upgraded to Buy from Neutral at Citi
Citi analyst Kenneth Wong upgraded Kornit Digital (KRNT) to Buy and raised his price target for the shares to $19 from $16. The recent selloff in shares presents an attractive opportunity ahead of the company's fiscal 2018 guidance in February, Wong tells investors in a research note. He believes new products, improved sales coverage and a sales ramp Amazon.com (AMZN) create an "ideal set-up" in the second half of the year.
GFF Griffon
$18.15

-0.05 (-0.27%)

03/09/18
SIDC
03/09/18
INITIATION
Target $24
SIDC
Buy
Griffon initiated with a Buy at Sidoti
Sidoti started Griffon with a Buy rating and a $24 price target.
KBAL Kimball International
$16.90

0.44 (2.67%)

TACO Del Taco
$14.45

-0.19 (-1.30%)

10/04/17
MAXM
10/04/17
NO CHANGE
MAXM
Del Taco valuation remains 'compelling,' says Maxim
Maxim analyst Stephen Anderson says that Del Taco remains a "growth at a reasonable price story" even after its late summer rally, and he continues to believe that its valuation is "compelling." He raised his Q3 comp sales growth estimate for the company to 4.8% from 4.3% as he expects the company to continue to benefit from menu innovations, "increasing the number of guest occasions," and adding new restaurants. The analyst also expects the company's 2017 EPS to come in slightly above expectations. He keeps a $19 price target and a Buy rating on the shares.
12/06/17
WELS
12/06/17
NO CHANGE
WELS
Tax reform-driven EPS accretion would be sizeable for restaurant sector, says Wells Fargo
Wells Fargo analyst Jeff Farmer says that small cap companies including Del Taco (TACO), Habit Restaurants (HABT), El Pollo Loco (LOCO), Shake Shack (SHAK) and Noodles & Company (NDLS) could see the largest EPS accretion tailwind from a reduced corporate tax rate, with Red Robin (RRGB), Restaurant Brands (QSR), Yum! Brands (YUM) and Bloomin' Brands (BLMN) the companies that could see the smallest tailwind. The analyst notes that recent restaurant sector rally indicates that virtually the entire sector has benefitted from anticipation of potential tax reform, with the most heavily shorted names seeing an amplified share price move.
12/22/17
MAXM
12/22/17
NO CHANGE
MAXM
Buy
Maxim names Dave & Buster's, Domino's and Del Taco as top 2018 restaurant picks
Maxim analyst Stephen Anderson expects the Tax Cut and Jobs Act to benefit some restaurant names more than others, calling out Habit Restaurants (HABT), Chipotle (CMG), and Zoe's Kitchen (ZOES), Dave & Buster's (PLAY), Domino's Pizza (DPZ) and Del Taco (TACO) as among those that may benefit "disproportionately" compared to sector peers. Anderson identifies Dave & Buster's, Domino's and Del Taco as his top restaurant picks for 2018 and keeps Buy ratings on all three. He also raised his price target on D&B to $97 from $84, on Domino's to $240 from $230 and on Del Taco to $20 from $19.
01/02/18
WELS
01/02/18
NO CHANGE
WELS
Potbelly, Del Taco may see largest EPS tailwind from tax reform, says Wells Fargo
Wells Fargo argues that Potbelly (PBPB), Del Taco (TACO), El Pollo Loco (LOCO) and Jack in the Box (JACK) could see the largest EPS accretion tailwind from a reduced corporate tax rate, with Restaurant Brands (QSR), Red Robin (RRGB), Noodles & Company (NDLS) and Yum! Brands (YUM) the companies that could see the smallest tailwind. Recent restaurant rally indicates that virtually the entire sector has benefited from anticipation of potential tax reform, with the most heavily shorted names seeing an amplified move, the firm adds.

TODAY'S FREE FLY STORIES

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

14:30
10/21/18
10/21
14:30
10/21/18
14:30
Conference/Events
Neon Therapeutics management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 26

    Oct

  • 07

    Nov

GTHX

G1 Therapeutics

$46.88

-0.07 (-0.15%)

14:13
10/21/18
10/21
14:13
10/21/18
14:13
Hot Stocks
G1 presents additional data from randomized Phase 2 trial in first-line SCLC »

G1 Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

NCNA

NuCana

$18.90

1.9 (11.18%)

14:09
10/21/18
10/21
14:09
10/21/18
14:09
Hot Stocks
NuCana reports additional data on NUC-1031 in advanced biliary tract cancer »

NuCana announced combined…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

, MRK

Merck

$72.34

0.12 (0.17%)

14:05
10/21/18
10/21
14:05
10/21/18
14:05
Hot Stocks
Leap Therapeutics presents esophagogastric cancer data »

Leap Therapeutics (LPTX)…

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

INCY

Incyte

$66.09

1.66 (2.58%)

14:02
10/21/18
10/21
14:02
10/21/18
14:02
Hot Stocks
Incyte announces positive interim data from Phase 2 trial of Pemigatinib »

Incyte announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:58
10/21/18
10/21
13:58
10/21/18
13:58
Hot Stocks
Loxo's larotrectinib delivers 81% ORR in expanded dataset of 109 TRK fusion cancer »

Bayer (BAYRY) and Loxo…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:53
10/21/18
10/21
13:53
10/21/18
13:53
Hot Stocks
Loxo announces larotrectinib clinical update in patients with TRK fusion cancers »

Loxo Oncology (LOXO)…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

13:45
10/21/18
10/21
13:45
10/21/18
13:45
Hot Stocks
Mirati announces updated data from ongoing trial of single agent sitravatinib »

Mirati Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

RHHBY

Roche

$0.00

(0.00%)

13:39
10/21/18
10/21
13:39
10/21/18
13:39
Hot Stocks
Entrectinib shrank tumors in people with NTRK fusion-positive solid tumors »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

GILD

Gilead

$73.27

-0.9 (-1.21%)

, GLPG

Galapagos NV

$107.66

2.29 (2.17%)

13:34
10/21/18
10/21
13:34
10/21/18
13:34
Hot Stocks
Gilead, Galapagos NV announced data from Phase 3 FINCH2 trial of filgotinib »

Gilead Sciences (GILD)…

GILD

Gilead

$73.27

-0.9 (-1.21%)

GLPG

Galapagos NV

$107.66

2.29 (2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 07

    Nov

BLRX

BioLineRx

$0.98

-0.22 (-18.33%)

, MRK

Merck

$72.34

0.12 (0.17%)

13:27
10/21/18
10/21
13:27
10/21/18
13:27
Hot Stocks
BioLineRx discloses additional data from Phase 2a COMBAT/KEYNOTE-202 study »

BioLineRx (BLRX)…

BLRX

BioLineRx

$0.98

-0.22 (-18.33%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

ADAP

Adaptimmune

$10.79

-0.09 (-0.83%)

13:22
10/21/18
10/21
13:22
10/21/18
13:22
Hot Stocks
Adaptimmune presents updated data from ongoing MAGE-A10, MAGE-A4 studies »

Adaptimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

13:02
10/21/18
10/21
13:02
10/21/18
13:02
Hot Stocks
Genentech's Tecentriq, Abraxane combo demonstrates positive Phase III results »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

PFE

Pfizer

$44.50

0.48 (1.09%)

12:56
10/21/18
10/21
12:56
10/21/18
12:56
Hot Stocks
Pfizer presents overall survival data from PALOMA-3 trial of Ibrance »

Pfizer announced detailed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

  • 07

    Nov

MRK

Merck

$72.34

0.12 (0.17%)

12:52
10/21/18
10/21
12:52
10/21/18
12:52
Hot Stocks
Merck presents early data for STING agonist in advanced solid tumors/lymphomas »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:47
10/21/18
10/21
12:47
10/21/18
12:47
Hot Stocks
Dynavax's SD-101, Keytruda combo still shows 70% ORR in Advanced Melanoma »

Dynavax (DVAX) presented…

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

12:44
10/21/18
10/21
12:44
10/21/18
12:44
Hot Stocks
Exelixis announces results from data analysis of CABOSUN, METEOR trials »

Exelixis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 01

    Nov

  • 07

    Nov

  • 27

    Nov

  • 14

    Jan

AGEN

Agenus

$1.97

-0.025 (-1.26%)

12:39
10/21/18
10/21
12:39
10/21/18
12:39
Hot Stocks
Agenus presents clinical data on PD-1, CTLA-4 at ESMO 2018 »

Agenus presented updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

OMED

OncoMed

$2.47

-0.17 (-6.44%)

12:37
10/21/18
10/21
12:37
10/21/18
12:37
Hot Stocks
OncoMed announces interim phase 1b results for Navicixizumab, Paclitaxel combo »

OncoMed Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:34
10/21/18
10/21
12:34
10/21/18
12:34
Hot Stocks
ImmunoGen presents initial data from FORWARD II expansion cohort »

ImmunoGen (IMGN)…

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 02

    Nov

  • 11

    Jan

  • 16

    Feb

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

12:30
10/21/18
10/21
12:30
10/21/18
12:30
Hot Stocks
Opdivo, Yervoy combo shows promising results in advanced form of bladder cancer »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

MRK

Merck

$72.34

0.12 (0.17%)

12:26
10/21/18
10/21
12:26
10/21/18
12:26
Hot Stocks
Merck's Keytruda shows complete response rate of nearly 40% in high-risk NMIBC »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

12:18
10/21/18
10/21
12:18
10/21/18
12:18
Hot Stocks
Tesaro presents Phase 1 GARNET data of TSR-042 in MSI-H endometrial cancer »

Tesaro summarized updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 07

    Nov

UDR

UDR, Inc.

09:37
10/21/18
10/21
09:37
10/21/18
09:37
Downgrade
UDR, Inc. rating change at Evercore ISI »

UDR, Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 07

    Nov

AVB

AvalonBay

$178.01

1.725 (0.98%)

09:37
10/21/18
10/21
09:37
10/21/18
09:37
Downgrade
AvalonBay rating change  »

AvalonBay downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.